Letters DPP-4 inhibitors in type 2 diabetes

No better than less expensive drugs

BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2914 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2914
  1. Thomas L Perry, clinical assistant professor 1,
  2. Stephen S Lippman, endocrinologist2,
  3. Mark McConnell, internist2,
  4. Aaron M Tejani, research associate1
  1. 1Therapeutics Initiative, University of British Columbia, BC, Vancouver, Canada, V6T 1Z3
  2. 2Veterans Administration, Sacramento, CA, USA
  1. tom.perry{at}ti.ubc.ca

The meta-analysis of short term studies using dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes indicates that they lower glycated haemoglobin (HbA1C) without causing weight gain or increasing mortality or serious adverse events. 1 In return, they increase drug costs.

However, drug treatment for type 2 diabetes aims to prevent or …

View Full Text

Log in

Log in through your institution


* For online subscription